CLINICAL STUDY PROTOCOL ADDENDUM 1

GERMANY

A Randomized Multi-Center, Double-Blind, Placebo-Controlled Study of a New Modified-Release Tablet Formulation of Prednisone (Lodotra®) in Patients with Rheumatoid Arthritis

Circadian Administration of Prednisone in RA

The CAPRA-2 Study

Development Phase: Phase III
Protocol No.: NP01-007

IND Number: 72,569
EudraCT Number: 2007-003508-36

Sponsor: Nitec Pharma AG
Kägenstrasse 17
4153 Reinach, Switzerland
www.nitecpharma.com

Date of Protocol: 17 January 2008
Date of Protocol Addendum: 17 April 2008

CONFIDENTIAL

The information contained in this document is the property of Nitec Pharma. The content of this document may not be disclosed to others than the investigator(s) and duly staff, applicable EC/IRB and regulatory authorities without written approval from Nitec Pharma, except to the extent necessary to obtain informed consent from those persons to whom the medication may be administered.
SIGNATURE PAGES

SPONSORS APPROVAL OF STUDY PROTOCOL ADDENDUM

This clinical study protocol addendum was subject to critical review and has been approved by the Sponsor.

Stephan Witte, PhD
Chief Medical Officer

Achim Schäffler, PhD
EVP R&D and Technical Operations

21-April-2008
Date

21-April-2001
Date
DECLARATION OF INVESTIGATOR

I agree to conduct this study in accordance with the requirements of this clinical study protocol addendum and also in accordance with the following:

- The principles of the “Declaration of Helsinki” (as amended in Tokyo, Venice, Hong Kong and South Africa)
- Good Clinical Practice, Respective local laws, and regulations

Signature of Coordinating Investigator

[Signature]
Prof. Dr. Frank Buttgereit

22 - April 2008
Date

Signature of Investigator at site

[Signature]
Investigator

Date
Rationale for this addendum

The purpose of this addendum was to include an additional exclusion criterion for Germany, since it was advised that the administration of glucocorticoids can lead to an increase of internal eye pressure.

Summary of changes

One additional exclusion criterion was added to the clinical study protocol.

To clearly highlight the changes made, the new text has been bolded (new text).

Protocol Synopsis, Page 8

Original text

Exclusion criteria:

The presence of any of the following will exclude a patient from study enrolment:

- Suffering from another disease, which requires glucocorticoid treatment, e.g. asthma or neurodermatitis
- Synovectomy within 4 months prior to study start
- Use of glucocorticoids (by any route) within 6 weeks prior to screening visit (Visit 0)
- Use of biologicals: tumor necrosis factor α (TNFα) inhibitors within 3 months prior to screening visit (Visit 0) or other compounds within 1 year prior to screening Visit 0
- Clinically relevant abnormal laboratory values suggesting an unknown disease and requiring further clinical evaluation
- Pregnancy or nursing
- Participation in another clinical study (use of an investigational product) within 30 days preceding Visit 0
- Re-entry of patients previously enrolled in this trial
- Suspected inability or unwillingness to comply with study procedures
- Alcohol or drug abuse
- Requirement of nonpermitted concomitant medication
- Known hypersensitivity to prednisolone
- Any contraindication for low dose prednisone treatment
- Significant renal impairment (serum creatinine > 150 μmol/L)
• Significant hepatic impairment (investigator’s opinion)
• Any uncontrolled concomitant disease requiring further clinical evaluation (e.g. uncontrolled diabetes, uncontrolled hypertension etc.)

New text

Exclusion criteria:

The presence of any of the following will exclude a patient from study enrolment:

• An existing family predisposition for glaucoma, except if a medical ophthalmological examination of intraocular eye pressure measurement reveals normal findings
• Suffering from another disease, which requires glucocorticoid treatment, e.g. asthma or neurodermatitis
• Synovectomy within 4 months prior to study start
• Use of glucocorticoids (by any route) within 6 weeks prior to screening visit (Visit 0)
• Use of biologicals: tumor necrosis factor α (TNFα) inhibitors within 3 months prior to screening visit (Visit 0) or other compounds within 1 year prior to screening Visit 0
• Clinically relevant abnormal laboratory values suggesting an unknown disease and requiring further clinical evaluation
• Pregnancy or nursing
• Participation in another clinical study (use of an investigational product) within 30 days preceding Visit 0
• Re-entry of patients previously enrolled in this trial
• Suspected inability or unwillingness to comply with study procedures
• Alcohol or drug abuse
• Requirement of nonpermitted concomitant medication
• Known hypersensitivity prednisolone
• Any contraindication for low dose prednisone treatment
• Significant renal impairment (serum creatinine > 150 μmol/L)
• Significant hepatic impairment (investigator’s opinion)
• Any uncontrolled concomitant disease requiring further clinical evaluation (e.g. uncontrolled diabetes, uncontrolled hypertension etc.)
4.5 EXCLUSION CRITERIA

Patients presenting with any of the following will not be included in the study:

- Suffering from another disease, which requires glucocorticoid treatment, e.g. asthma, neurodermatitis
- Synovectomy within 4 months prior to study start
- Use of glucocorticoids (by any route) within 6 weeks prior to screening Visit 0
- Use of biologicals: TNFα inhibitor within 3 months prior to screening Visit 0, other compounds within 1 year prior to screening Visit 0
- Clinically relevant abnormal laboratory values suggesting an unknown disease and requiring further clinical evaluation
- Pregnancy or nursing
- Participation in another clinical study (use of an investigational product) within 30 days preceding Visit 0
- Re-entry of patients previously enrolled in this trial
- Suspected inability or unwillingness to comply with study procedures
- Alcohol or drug abuse
- Requirement of nonpermitted concomitant medication
- Known hypersensitivity to prednisone or prednisolone
- Any contraindication for low dose prednisone treatment
- Significant renal impairment (serum creatinine > 150 µmol/L)
- Significant hepatic impairment (investigator’s opinion)
- Any uncontrolled concomitant disease requiring further clinical evaluation (e.g. uncontrolled diabetes, uncontrolled hypertension etc.)
4.5 EXCLUSION CRITERIA

Patients presenting with any of the following will not be included in the study:

- An existing family predisposition for glaucoma, except if a medical ophthalmological examination of intraocular eye pressure measurement reveals normal findings
- Suffering from another disease, which requires glucocorticoid treatment, e.g. asthma, neurodermatitis
- Synovectomy within 4 months prior to study start
- Use of glucocorticoids (by any route) within 6 weeks prior to screening Visit 0
- Use of biologicals: TNFα inhibitor within 3 months prior to screening Visit 0, other compounds within 1 year prior to screening Visit 0
- Clinically relevant abnormal laboratory values suggesting an unknown disease and requiring further clinical evaluation
- Pregnancy or nursing
- Participation in another clinical study (use of an investigational product) within 30 days preceding Visit 0
- Re-entry of patients previously enrolled in this trial
- Suspected inability or unwillingness to comply with study procedures
- Alcohol or drug abuse
- Requirement of nonpermitted concomitant medication
- Known hypersensitivity to prednisone or prednisolone
- Any contraindication for low dose prednisone treatment
- Significant renal impairment (serum creatinine > 150 µmol/L)
- Significant hepatic impairment (investigator’s opinion)
- Any uncontrolled concomitant disease requiring further clinical evaluation (e.g. uncontrolled diabetes, uncontrolled hypertension etc.)